Bayer AG delivered Q1 2026 earnings per share of $0.80, surpassing the $0.64 estimate, and posted revenue of $15.79 billion versus a $15.77 billion consensus. Net profit improvement was bolstered by both operational gains and one-time proceeds from the antibiotics business sale.

The Crop Science division achieved a 9% increase in operating profit as higher volumes and pricing in seeds and crop protection products fueled growth. A strategic divestiture of the antibiotics unit further enhanced divisional margins.

The company’s debt-to-equity ratio stands at 1.44, reflecting significant leverage relative to equity, while a current ratio of 0.996 indicates nearly balanced short-term assets and liabilities, highlighting its immediate liquidity position.